Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination Therapy
This study will review published trial literature and documents for Overall Survival (OS) to evaluate the association between the hazard of death and each baseline variable.
Melanoma
OTHER: Non-Interventional
Prognostic Model of Overall Survival (OS), The OS prognostic model uses Individual patient data from a pooled analysis of 12 ipilimumab studies., 10 years
This study will review published trial literature and documents for Overall Survival (OS) to evaluate the association between the hazard of death and each baseline variable.